Episode Details

Scientists have unlocked a game-changing breakthrough with daraxonrasib, a new drug that nearly doubles survival time for advanced pancreatic cancer patients—offering hope where there was once little. In a global trial of 500 patients, those on the drug lived an average of 13.2 months, compared to just 6.6 months on standard chemo. Targeting the KRAS gene mutation found in 90% of pancreatic tumors, daraxonrasib also delivers fewer brutal side effects. Experts are calling it “landscape-changing,” and patient advocates are celebrating it as one of the most promising advances in years—because every extra month means more time with loved ones. The drug’s simple daily dose and improved tolerability make it a major leap forward, now focused on rapid access for those who need it most.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/685555e2afbb48f8